The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $142.28

Today's change-3.74 -2.56%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $142.28

Today's change-3.74 -2.56%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc down (U.S.)$3.74

Alexion Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$3.74 or 2.56% to (U.S.)$142.28. Over the last five days, shares have lost 2.50% and are down 25.41% for the last year to date. This security has underperformed the S&P 500 by 11.30% during the last year.

Key company metrics

  • Open(U.S.) $146.20
  • Previous close(U.S.) $146.02
  • High(U.S.) $146.90
  • Low(U.S.) $139.13
  • Bid / Ask-- / --
  • YTD % change-25.41%
  • Volume2,132,320
  • Average volume (10-day)2,542,432
  • Average volume (1-month)1,876,147
  • Average volume (3-month)1,679,211
  • 52-week range(U.S.) $130.51 to (U.S.) $208.88
  • Beta0.92
  • Trailing P/E186.21×
  • P/E 1 year forward27.29×
  • Forward PEG1.36×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.76
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+5.54%

Based on its net profit margin of 5.54%, Alexion Pharmaceuticals Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue667636600599
Total other revenue--------
Total revenue667636600599
Gross profit613584531550
Total cost of revenue54526949
Total operating expense512455497396
Selling / general / administrative213221187184
Research & development161126216125
Depreciation / amortization41654
Interest expense (income), net operating--------
Unusual expense (income)43501933
Other operating expenses, total--------
Operating income155181104204
Interest income (expense), net non-operating-----1-1
Gain (loss) on sale of assets--------
Other--------
Income before tax139177107205
Income after tax-18417091153
Income tax, total32371652
Net income-18417091153
Total adjustments to net income--------
Net income before extra. items-18417091153
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-18417091153
Inc. avail. to common incl. extra. items-18417091153
Diluted net income-18417091153
Dilution adjustment--------
Diluted weighted average shares226205202202
Diluted EPS excluding extraordinary itemsvalue per share-0.810.830.450.76
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.691.070.530.88